Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Nov
20
Today In Oncology
Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC
Melanoma Cancer Cluster Found in Parts of Pennsylvania
FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC
Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma
Vorasidenib in IDH1/2-Mutant Low-Grade Glioma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo